The U.S. Food and Drug Administration (FDA) has approved Makena (hydroxyprogesterone caproate) injection to reduce the risk of preterm delivery in pregnant women with a history of at least one spontaneous preterm birth. Read more here.
FDA approves drug to reduce risk of preterm birth
Most Recent Content
For Nurse Practitioners
Do Vitamins, Plants Help Uterine Fibroid Risk or Treatment?
A research team out of Poland recently undertook a comprehensive examination of published data to determine the role that vitamins and diet might play...
